LATEST NEWS

Approved Marine Drugs

© 2021-2023 Marine Pharmacology

August 2023

All links were checked and working properly.
Clinical trial numbers were updated accordingly.
o Cytarabine US clinical trials from 434 to 432 and European clinical trials from 127 to 126
o Vidarabine US clinical trials from 23 to 22
o Eribulin Mesylate US clinical trials from 66 to 68
o Brentuximab vedotin US clinical trials from 84 to 82
o Trabectedin US clinical trials from 21 to 20
o Polatuzumab vedotin US clinical trials from 37 to 39
o Disitamab vedotin US clincal trials from 47 to 51 and Chinese clinical trials from 8 to 10

July 2023

All links were checked and working properly.
Clinical trial numbers were updated accordingly.
o Cytarabine US clinical trials from 440 to 434 and Chinese clinical trials from 53 to 54
o Vidarabine US clinical trials from 24 to 23
o Omega-3-acid ethyl esters US clinical trials from 20 to 18
o Eicosapentaenoic acid ethyl ester US clinical trials from 4 to 7
o Eribulin Mesylate US clinical trials from 33 to 66 and Chinese clinical trials from 9 to 10
o Brentuximab vedotin US clinical trials from 71 to 84
o Trabectedin US clinical trials from 19 to 21
o Polatuzumab vedotin US clinical trials from 25 to 37
o Enfortumab vedotin US clinical trials from 21 to 28, European clinical trials from 10 to 11, and Chinese clinical trials from none to 1
o Lurbinectedin US clinical trials from 23 to 24
o Disitamab vedotin US clincal trials from 32 to 47 and Chinese clinical trials from 7 to 8

June 2023

All links were checked and working except the Chinese Clinical Trials links. Chinese clinical trials links were checked for all and updated to:
- Cytarabine from this to the new link
- Eribulin mesylate from this to the new link
- Brentuximab vedotin from this to the new link
- Panbinostat from this to the new link
- Disitamab vedotin from this to the new link
The year-of-FDA-approval link for the Blenrep withdrawal was updated.
Panobinostat (Farydak®) and Belantamab Mafodotin-blmf (Blenrep™) were withdrawn from accelerated approval and removed from the table.
It was noted in the drug table that Omega-3-carboxylic acid (Epanova®) was discontinued in 2021.
The Molecular Target was corrected for Panobinostat to deacetylase, Plitidepsin to eEF1A2, Polutuzumab vedotin to CD79b and microtubules, Enfortumab vedotin-ejfv to Nectin-4 and microtubules, Disitimab vedotin to HER2 and microtubules, and Tisotumab vedotin-tftv to TF and microtubules.
Clinical trial numbers were updated accordingly.
- Cytarabine US clinical trials from 428 to 440 and Chinese clinical trials from 48 to 53.
- Vidarabine US clinical trials from 23 to 24.
- Omega-3-acid ethyl esters US clinical trials from 22 to 20.
- Eribulin mesylate US clinical trials from 35 to 33, European clinical trials from 21 to 22, and Chinese clinical trials from 8 to 9.
- Trabectedin US clinical trials from 20 to 19.
- Enfortumab vedotin US clinical trials from 19 to 21 and European clinical trials from 9 to 10.
- Lurbinectedin US clinical trials from 21 to 23.
- Belantamab mafodotin US clinical trials from 34 to 39 and European clinical trials from 17 to 19.
- Disitamab vedotin US clinical trials from 29 to 32 and Chinese clinical trials from 6 to 7.
- Tisotumab vedotin US clinical trials from 3 to 4.

April 2023

All links were checked and are working properly.
- In January we changed Arasena A to the current link, which was not working in early April. At the time of our meeting, it was working again, so we did not to change the link.
Clinical trial numbers were updated accordingly.
- Cytaribine US clinical trials from 425 to 428, European clinical trials from 125 to 127, and Chinese clinical trials from 47 to 48
- Vidarabine US clinical trials from 21 to 23
- Ziconotide US clinical trials from 1 to 2
- Omega-3-acid ethyl esters US clinical trials from 24 to 22
- Eicosapentaenoic acid ethyl ester US clinical trials from 5 to 4
- Eribulun Mesulate US clinical trials from 36 to 35
- Brentuximab vedotin US clinical trials from 70 to 69, European clinical trials from 39 to 40
- Trabectedin US clinical trials from 21 to 20, European clinical trials from 23 to 22
- Panbinostat US clinical trials from 12 to 11
- Plitidepsin US clinical trials from 2 to 1
- Polutuzumab vedotin US clinical trials from 23 to 25
- Enfortumab vedotin US clinical trials from 18 to 19
- Lurbinectedin European clinical trials from 4 to 5
- Disitimab vedotin US clinical trials from 28 to 29

March 2023

All links were checked and are working properly.
Clinical trial numbers were updated accordingly.
- Cytaribine US clinical trials from 427 to 425
- Vidarabine US clinical trials from 22 to 21
- Ziconitide US Clinical trials from 2 to 1
- Eicosapentaenoic acid ethyl ester European clinical trials from 4 to 2
- Brentuximab vedotin US clinical trials from 72 to 70, European clinical trials from 39 to 38
- Polatuzumab vedotin US clinical trials from 22 to 23
- Lurbinectedin US clinical trials from 20 to 21
- Belantamab mafodotin US clinical trials from 33 to 34
- Disitimab vedotin US Clinical trials from 26 to 28 and Chinese clinical trials from 4 to 6

February 2023

All links were checked and are working properly.
- The Omega-3-carboxylic acid (Epanova) trials for Europe were pulling completed studies. I rechecked with looking only for ongoing studies.
Clinical trial numbers were updated accordingly.
- Cytarabine US clinical trials went from 426 to 427, European clinical trials from 126 to 125, and Chinese clinical trials from 46 to 47
- Omega-3-carboxylic acid trials were updated from 8 to 0, accounting only for ongoing studies
- Erubilin mesylate Chinese clinical trials were updated from 7 to 8
- Panbinostat US clinical trials were updated from 13 to 12
- Plitidepsin US clinical trials were updated from 1 to 2
- Enfortumab vedotin US clinical trials were udated from 19 to 18
- Lurbinectedin US clinical trials were updated from 21 to 20

January 2023

All links were checked and working properly except the Arasena A prescription link. The Arasena A link https://www.nlm.nih.gov/pubs/techbull/ja22/ja22_pubchem.html was updated December 16th, and no longer shows the prescribing information. It has been updated to https://www.gnhindia.com/products/nz-drugs/vira-a-solution-for-infusion-200-mg-ml/.
Chinese cliinical trials links are again working.
Clinical trial numbers were updated accordingly.
- Cytarabine US clinical trials from 430 to 426, European clincal trials from 128 to 126, and Chinese clinical trials from 45 to 46
- Omega-3-acid ethyl esters US clinical trials from 23 to 24
- Brentuximab vedotin US clinical trials from 73 to 72 and European clinical trials from 40 to 39
- Panbinostat US clincal trials from 14 to 13 and European clinical trials from 8 to 7
- Plitidepsin European clinical trials from 2 to 3
- Polatuzumab vedotin European clinical trials from 3 to 2
- Enfortumab vedotin US clinical trials from 18 to 19
- Lurbinectedin US clinical trials from 17 to 21 and European clincal trials from 3 to 4
- Disitimab vedotin Chinese clinical trials from 3 to 4

December 2022

All the links have been checked and were working properly, except links addressing compounds in Chinese clinical trials. We are working with Dr. Jinbo Yang's group to update these links.
The approved marine-derived pharmaceutical Belantamab Mafoditin-blmf (Blenrep) withdrawal process was initiated on 11-22-2022, following the request of the FDA. The agency's request was based on the previously announced outcome of the Phase III DREAMM-3 confirmatory trial, which did not meet the requirements of the FDA accelerated approval regulations. (https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-blenrep-us-marketing-authorisation/).
Clinical trials numbers were updated accordingly.
- Cytarabine European clinical trials from 132 to 128
- Vidarabine US clinical trials from 48 to 22
- Omega-3-acid ethyl esters US clinical trials from 24 to 23
- Erubilin mesylate US clinical trials from 38 to 36
- Panbinostat US clinical trials from 15 to 14
- Polutuzumab vedotin US clinical trials from 23 to 22
- Belantamab mafodotin US clinical trials from 31 to 33 and European clinical trials from 14 to 17
- Disitimab vedotin US clinical trials from 23 to 26

October 2022

All the links have been checked and were working properly.
The number of current clinical trials was updated accordingly.
- Cytarabine Chinese clinical trials from 43 to 45
- Vidarabine US clinical trials from 49 to 48
- Erubilin mesylate US clinical trials from 36 to 38
- Brentuximab vedotin US clinical trials from 74 to 73 and European clinical trials from 42 to 40
- Trabectedin US clinical trials from 22 to 21
- Enfortumab vedotin US clinical trials from 17 to 18
- Lurbinectedin US clinical trials from 18 to 17
- Belantamab mafodotin US clinical trials from 29 to 31
- Disitimab vedotin US clinical trials from 20 to 23 and Chinese clinical trials from 1 to 3

September 2022

Copyright notices were posted on the top and bottom of this page.
All the links have been checked and were working properly.
The approved marine-derived pharmaceutical Panobinostat (Farydak) was withdrawn on 3-24-2022, and a notice was issued by the Federal Register was added to the webpage (https://www.federalregister.gov/documents/2022/03/24/2022-06182/secura-bio-inc-withdrawal-of-approval-of-new-drug-application-for-farydak-panobinostat-capsules-10).